The drug they repurposed is like 30 years old. It's proved it's safe. This is working. It is producing like 50 to 70% better outcomes. And yet The FDA has given both of these drugs their what they call the concluding was a complete resolution letter, the no letter, just under completely bogus terms. One of them that said, well there are like cracks in the floor of the manufacturing facility. So there's some manufacturing issues. The other one just said, well you don't have real world data. (41:53–42:08)
CLAIM
Asserts that the FDA rejected two drugs for rare diseases under questionable terms.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
